Other National Policy Areas
ASAM supports a wide variety of measures to prevent and research substance-related problems.
ASAM is committed to increasing access to and improving the quality of evidence-based addiction prevention services. ASAM supports a wide variety of measures to prevent substance-related problems, understanding that carefully planned prevention measures can reduce the initiation of substance use. Additionally, ASAM advocates for a robust research agenda informed by patient experience and clinical needs. Specific research priorities include effective prevention programs and pharmacological and non-pharmacological treatments for addiction and improved medical treatments for stimulant use disorder.
ASAM is committed to pursuing advocacy initiatives that advance racial justice and improve the health of all people suffering from addiction.
Cannabis Policy Reform
Learn more about ASAM’s efforts to advance cannabis decriminalization while protecting the health and safety of patients.
In this 2020 public policy statement on cannabis, ASAM reviews the medical and social science literature about cannabis use and recommends important, evidence-based policy changes that mitigate potential harm related to cannabis use in the United States. As the medical community continues to document evidence of the harms and potential benefits of cannabis use, ASAM calls for the decriminalization of cannabis use, alongside appropriate regulations and oversight that protect public health.
ASAM supports the Cannabidiol and Marijuana Research Expansion Act, which would work to ensure that research on CBD and other potentially beneficial marijuana-derived substances is based on sound science while simultaneously reducing the regulatory barriers associated with conducting research on marijuana. Read more.
The COVID-19 pandemic has changed the telehealth practice landscape for addiction medicine. Learn more about the state of telehealth for addiction medicine and ASAM’s efforts to advance telehealth reform.
On September 16, 2021, ASAM submitted a comment letter to the Centers for Medicare & Medicaid Services (CMS) outlining suggested improvements to the proposed Physician Payment Schedule for calendar year (CY) 2022. Among other recommendations, ASAM urged that CMS extend audio-only telehealth flexibilities for opioid treatment programs services as well as other substance use disorder services. ASAM underscored the need for federal initiative to expand access to treatment more widely. To read CMS’ Calendar Year (CY) 2022 Medicare Physician Fee Schedule Final Rule, click here.
This legislation would make permanent a new, audio-video, telehealth evaluation exception to the Ryan Haight Act’s in-person exam requirement, which would allow clinicians to prescribe certain addiction treatment medications, like buprenorphine, to new patients through telehealth.
ASAM envisions a future where everyone has access to tobacco cessation treatments. Learn more about our efforts to prevent tobacco use and expand access to tobacco cessation treatments.
ASAM endorsed the Quit Because of COVID-19 Act which would ensure that all Medicaid and Children's Health Insurance Program (CHIP) enrollees have access to the full array of evidence-based tobacco cessation treatments. Specifically, the bill would extend comprehensive tobacco cessation to all Medicaid and CHIP beneficiaries, eliminate cost sharing and prior authorization requirements, and would provide enhanced federal funding to cover the full cost of state outreach campaigns to education providers and Medicaid and CHIP beneficiaries about the benefit. Read more.